Online inquiry

IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2116MR)

This product GTTS-WQ2116MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IFNAR1&IFNAR2 gene. The antibody can be applied in Hepatitis C research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000629.3; NM_000874.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3454; 3455
UniProt ID P17181; P48551
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ2116MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7895MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA GSK-249320
GTTS-WQ13064MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ15804MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb14045
GTTS-WQ7317MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FPA-144
GTTS-WQ2517MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 334
GTTS-WQ3363MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AT-004
GTTS-WQ10349MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY 3090106
GTTS-WQ14858MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SGN-CD33A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW